Healthy, Heart Failure
Conditions
Keywords
Desensitization, beta adrenergic receptors, Healthy subjects
Brief summary
A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is thought to play a major role in the pathogenesis of diseases such as congestive heart failure. However, currently, there is no in vivo model that will enable us to measure desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo. Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1 adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic responses to dobutamine over time.
Interventions
DRUG3 hours intravenous dobutamine
Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
Sponsors
Hadassah Medical Organization
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy subjects
Exclusion criteria
* consumption of any medications during the 2 weeks prior to the study * history of chest pain or tachycardia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heart rate | 3 hours |
Secondary
| Measure | Time frame |
|---|---|
| Systolic blood pressure | 3 hours |
Countries
Israel
Outcome results
None listed